Skip to main content
Home / Resources / Blog / 3 Takeaways from the FDA Oligo Guidance You Need to Know

3 Takeaways from the FDA Oligo Guidance You Need to Know

In June 2022, the FDA published their first oligonucleotide clinical pharmacology specific guidance [1]. This is a welcome addition and clarifies the position of the agency on some key aspects regarding development of oligonucleotide therapies. Whilst the guidance still leaves a few open questions, it provides drug developers with a starting point and acknowledges that oligonucleotides present some unique aspects and challenges.

In this blog, we’ll discuss the new guidance and highlight our 3 key takeaways and share our wish list for the next guidance!

But first – what is an oligonucleotide?

This class of single- or double-stranded small synthetic nucleic acid polymers (≈20-mer) can be used to modulate gene expression. Oligonucleotides, or “oligos” for short, modulate gene expression via various mechanisms. They can target pre-mRNA, mRNA, or non-coding RNA to induce degradation, modulate splicing events, or interfere with protein translation (Figure 1).

Currently, 15 oligos are approved across various territories for use in patients with rare diseases, with the first FDA oligo approved— fomivirsen— in 1998. Oligos have some specific pharmacokinetic (PK) properties compared to small molecule drugs. They have very low oral bioavailability (hence intravenous or subcutaneous are preferred routes of administration), high distribution in tissues (typically in the liver, kidney, spleen, and lymph nodes), no or very low blood brain penetration, rapid plasma clearance, and degradation via nucleases within tissues, which results in a very long residence time. Learn more about the PK of oligonucleotides in this blog [2].

Knockdown of IncRNAs: Exploring RNAi and antisense oligo methods
Figure 1 adapted from Knockdown of IncRNAs: Exploring RNAi and antisense oligo methods [Digital image]. (n.d.). Retrieved January 27, 2021, from

Our top 3 takeaways from this guidance

1) Drug-drug interaction (DDI) expectations

How concerned we need to be about the DDI potential of oligos has previously been uncertain. In the new guidance, the FDA doesn’t require assessment of the oligo as an in vitro substrate for CYP450 enzymes or transporters – unless there is substantial renal active secretion, in which case they suggest in vitro assessment of renal transporters may be important. They want sponsors to assess the ability of oligos to modulate CYP450 enzymes and transporters though, and these stay recommended, even if a well-founded justification could be tested during interaction with agencies!

2)  Immunogenicity assessment is expected

Immunogenicity is the ability of a foreign substance, such as a drug treatment, to provoke an immune response. Historically, the immunogenicity assessment of oligos has been somewhat patchy – with some programs including it and others not. For example, inclisiran approved in 2021 [3] included anti-drug antibody (ADA) assessment on their drug label, whereas casimersen approved in the same year didn’t [4]. The FDA guidance has clarified that they expect an immunogenicity risk assessment completed for oligos. The assessment includes a multi-tiered immunogenicity assay approach on the product itself, the carrier component, or its targeted modified protein. Whilst this will be more burdensome for sponsors who hadn’t planned for this, it makes sense from a patient perspective while we explore further this aspect of oligos.

3) No surprises regarding QTc or organ impairment

Clinical pharmacology assessments for QTc and organ impairment refer to the risk of a drug causing QT prolongation (a risk factor for cardiotoxicity; Figure 2) and the potential need for dose adjustment in patients with renal or hepatic impairment, respectively. QTc and organ impairment sections are included in the guidance. However, the recommendations are less oligo specific, and the existing guidances on QTc and renal or hepatic impairment relevant to small molecules are referred to [5-9].

Drug prolongation of the QT interval of an ECG
Figure 2. Some drugs can cause prolongation of the QT interval of an ECG. Adapted from van Leeuwen, Roelof W F; van Gelder, Teun; Mathijssen, Ron H J; Jansman, Frank G A (2014). Drug–drug interactions with tyrosine-kinase inhibitors: a clinical perspective. The Lancet Oncology, 15(8), e315–e326. doi:10.1016/S1470-2045(13)70579-5 

Perhaps most interesting for oligos is the potential impact of renal impairment, which is discussed in more depth in this blog [10]. Drug developers will likely continue to discuss this topic with the FDA as we gain more insight on potential impacts or otherwise.

Future thinking

This guidance has whet out appetite for more! Other areas where it would be great to firm up thinking are:

  • Excretion balance in human: in the new guidance, the FDA mention identifying “the role of the liver and kidney in the disposition and elimination of the oligonucleotide therapeutic by considering in vitro, preclinical, and early Phase 1 clinical data.” Indeed, excretion balance studies are very complex whether in preclinical species or in the clinic due to very long elimination of product from the body. It remains difficult to document elimination pathways of oligos using a standard excretion balance study. Metabolism is typically via nucleases to produce chain-shortened metabolites that are not easy to quantify without a standard excretion balance study
  • Bioanalysis: achieving a limit of quantification that allows measurable concentrations long enough to observe different distribution and elimination phases is challenging for this type of product.
  • Use of allometric scaling: an advantage of oligos is that we can observe good interspecies allometry that proves very useful for first-in-human (FIH) dose determination. Oligos have high distribution into tissues, which can present challenges of how to relate a patient’s plasma concentrations to what’s happening at the site of action, especially when we don’t have an easy biomarker to measure and follow. Use of preclinical tissue:plasma concentration ratios can help inform on what we might expect in the clinic. This high distribution into tissues with the associated long residence time also has potential impact on safety evaluation – another area that would be worthy of further thinking

In summary – the new oligos guidance didn’t deliver many big surprises. However, it’s a big step forward to gain oligo specific guidance that provides clarity about what we need to do and don’t need to do when developing oligos. We look forward to seeing the guidance evolve over time to cover even more of the common questions we have as developers of oligo therapeutics.

Need guidance with your oligo program? Click here to learn how we’ve supported the success of 23 oligonucleotides programs, and how we can help you!


[1] FDA draft guidance. Clinical pharmacology considerations for the development of oligonucleotide therapeutics. Jun 2022.

[2] Certara blog. Beliveau. M. Maximising oligonucleotide therapeutic development: pre-clinical and translational considerations.

[3] Inclisiran FDA label. Dec 2021.

[4] Casimersen FDA label. Feb 2021.

[5] E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential 124 for Non-Antiarrhythmic Drugs. Oct 2012.

[6] E14 Clinical Evaluation of QT/QTc 125 Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs Questions 126 and Answers (R3). Jun 2017.

[7] FDA guidance. Enhancing the Diversity of Clinical Trial Populations —Eligibility Criteria, Enrollment Practices, and Trial Designs. Nov 2020.

[8] FDA draft guidance. Pharmacokinetics in Patients with Impaired Renal Function – Study Design, Data Analysis, and Impact on Dosing and Labeling. Sept 2020.

[9] Sahre MD, L Milligan, R Madabushi, RA Graham, KS Reynolds, A Terzic, J Benjamin, GJ Burckart, SM Huang, R Schuck, AM Thompson, and I Zineh. Evaluating patients with impaired renal function during drug development: Highlights from the 2019 US FDA pharmaceutical science and clinical pharmacology advisory committee meeting. Clin Pharmacol Ther. 2021;110(2):285-288. doi: 10.1002/cpt.2151. Epub 2021 Feb 16.

[10] Certara blog. Berglund EG, Gosselin NH. 8 tips for successfully developing oligonucleotide therapies.

About the authors

Kathryn Brown
By: Kathryn Brown

Kathryn is a clinical pharmacology consultant and Team Lead within the Integrated Drug Development group at Certara. In addition, she leads the Complex Biologics Integrated Practice Area that specialises in providing clients with expert support in areas such as cell therapies, RNA technologies, gene therapies, fusion proteins, ADCs, bispecific antibodies, etc. Prior to joining Certara in 2020, Kathryn worked in clinical pharmacology & pharmacometrics in the pharmaceutical industry for more than 20 years, working across all phases of development.

Marie-Cecile Secouard, PharmD
By: Marie-Cecile Secouard, PharmD

Marie-Cecile Secouard, PharmD, has been an Associate Director in Clinical Pharmacology at Certara since early 2022. She is a pharmacist by training with a Master of Science degree in Pharmacokinetics from the University Paris Descartes, France. Marie-Cecile has 12 years of experience working in the pharmaceutical industry as clinical project manager and clinical pharmacology project leader. She has experience with small molecules and biologics from phase I to post-approval in neurology, oncology, cardiology, and pediatric diseases. Extensively involved in the development plan of an antisense oligonucleotide in the past, she is part of the Complex Biologics Integrated Practice Area at Certara.

Powered by GlobalLink OneLink Software